CVR-CRUSH (COVID-19 Drug-Screening and Resistance Hub) is a fully integrated hub dedicated to accelerating antiviral therapeutic discovery for SARS-CoV-2 and other high consequence viruses. CRUSH was established with the support of LifeArc and, in part, from the UK Medical Research Council (MRC). LifeArc and the University of Dundee Drug Discovery Unit are strategic partners of CRUSH.